Trending at Lumira Ventures

Aurinia Doses First Patient in AURORA Phase 3 Clinical Trial of Voclosporin in Lupus Nephritis

admin Aurinia Pharmaceuticals, Portfolio News

VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH/TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced that the first patient has been dosed in AURORA, the Company’s Phase 3 confirmatory clinical …

Aurinia Closes US$173.1 Million Public Offering of Common Shares and Full Exercise of Underwriters’ Option to Purchase Additional Common Shares

admin Aurinia Pharmaceuticals, Portfolio News

VICTORIA, British Columbia–(BUSINESS WIRE)– Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) (“Aurinia” or the “Company”), a clinical stage biopharmaceutical company focused on the global immunology market, today announced the closing of its previously announced underwritten public offering of 25,645,000 common shares, including …

Aurinia Announces Presentations at the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) Meeting

admin Aurinia Pharmaceuticals, Portfolio News

May 12, 2016 06:00 PM Eastern Daylight Time VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)(TSX:AUP) (“Aurinia” or the “Company”) announced three presentations including the first scientific abstract of multi-targeted therapy (MTT) utilizing voclosporin in the treatment of lupus nephritis at …

Aurina Receives FDA Fast Track Designation for Voclosporin for the Treatment of Lupus Nephritis

admin Aurinia Pharmaceuticals, Portfolio News

VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH / TSX:AUP) (“Aurinia” or the “Company”) announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for voclosporin, the Company’s next generation calcineurin inhibitor, for the treatment of …

Aurinia Pharmaceuticals Announces Outcome from Data and Safety Monitoring Board for Its Phase 2b Study in Lupus Nephritis – Study to Continue as Planned

admin Aurinia Pharmaceuticals, Portfolio News

November 24, 2015 08:30 AM Eastern Standard Time    VICTORIA, British Columbia–(BUSINESS WIRE)–Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH-TSX:AUP) (“Aurinia” or the “Company”) has announced today that the independent Data and Safety Monitoring Board (“DSMB”) for the Company’s Phase 2b lupus nephritis study, …